Epidemiology of Infections and Development of Asthma - 06/07/19

Doi : 10.1016/j.iac.2019.03.001

Jenny Resiliac, BA ^a,^b,^c, Mitchell H. Grayson, MD ^a,^b,^c,^⁎
^a Center for Translational and Clinical Research, The Research Institute at Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH 43205, USA
^b Biomedical Sciences Graduate Program, The Ohio State University College of Medicine, Columbus, OH, USA
^c Division of Allergy and Immunology, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA

^∗Corresponding author. Division of Allergy and Immunology, Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, OH 43205.Division of Allergy and ImmunologyNationwide Children’s Hospital700 Children’s DriveColumbusOH43205

Résumé

Asthma and allergic diseases have become more prevalent, although the reasons for this increase in disease burden are not known. Understanding why these diseases have become more common requires knowledge of the disease pathogenesis. Multiple studies have identified respiratory viral infections and atypical bacteria as potential etiologic agents underlying the development of asthma (and possibly allergies). This review discusses the epidemiology and potential mechanistic studies that provide links between these infectious agents and the development (and exacerbation) of asthma. These studies provide insight into the increase in disease prevalence and have identified potential targets for future therapeutic intervention.

Le texte complet de cet article est disponible en PDF.

Keywords : Asthma, Allergy, Respiratory virus, Atypical bacteria, Epidemiology

Plan

Key points

Introduction

Epidemiology of infections and asthma

Viral infections and development of asthma

Respiratory syncytial virus and the development of asthma

Enteroviruses and asthma

Influenza and asthma

Atypical bacterial infection and the development of asthma

Summary

Disclosures: J. Resiliac has no disclosures; M.H. Grayson is the editor of this edition of Immunology and Allergy Clinics, has been on the advisory board for AstraZeneca, has received research funds from the National Institutes of Health and the Research Institute at Nationwide Children's Hospital, is an Associate Editor for the Annals of Allergy, Asthma, and Immunology, and is on the board of directors of the American Board of Allergy and Immunology, the Asthma and Allergy Foundation of America, and the American Academy of Allergy, Asthma, and Immunology.

Funded by: NIH Grant number(s): HL087778, NIHMS-ID: 1523912.